Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Investigating fatty acid metabolism in hepatocellular carcinoma patients

Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the heterogeneity of hepatocellular carcinoma (HCC) has not been established.

30 Dec 2024

The "Goldilocks" zone: A key to cellular adaptability and resilience

In a discovery that could redefine how we understand cellular resilience and adaptability, scientists at Scripps Research have unlocked the secret interactions between a primordial inorganic polymer of phosphate known as polyphosphate (polyP), and two basic building blocks of life: DNA and the element magnesium.

24 Dec 2024

New SIMPL2 platform revolutionizes the study of protein-protein interactions

A team led by researchers at the University of Toronto has created a platform, called SIMPL2, that revolutionizes the study of protein-protein interactions by simplifying detection while improving measurement accuracy.

23 Dec 2024

New modular strategy reduces piperidine synthesis steps for pharmaceuticals

A team of chemists from Scripps Research and Rice University has unveiled a novel method to simplify the synthesis of piperidines, a key structural component in many pharmaceuticals. The study, published in Science, combines biocatalytic carbon-hydrogen oxidation and radical cross-coupling, offering a streamlined and cost-effective approach to create complex, three-dimensional molecules. This innovation could help accelerate drug discovery and enhance the efficiency of medicinal chemistry.

20 Dec 2024

Vanderbilt researchers achieve milestone in Alzheimer's drug development

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a phase I single ascending dose clinical trial of VU319, a drug for memory loss in people with Alzheimer's disease and schizophrenia.

19 Dec 2024

Space experiment shows faster maturation of brain organoids in microgravity

Microgravity is known to alter the muscles, bones, the immune system and cognition, but little is known about its specific impact on the brain.

18 Dec 2024

Plymouth researchers lead initiative to advance the study of meningiomas in NF2-SWN

Researchers at the University of Plymouth are leading an innovative initiative to advance the study of meningiomas in NF2-related schwannomatosis (NF2-SWN).

18 Dec 2024

bit.bio raises $30 million led by M&G Investments

bit.bio, the global leader in cell programming technology, today announced the successful closing of a $30 million financing round led by M&G Investments, a leading international savings and investment company.

18 Dec 2024

Photocatalysed flow method accelerates synthesis of potent MC4R antagonist

Asynt report that the Cresswell Group, led by Dr Alexander J. Cresswell at the University of Bath (UK), have demonstrated the synthesis of novel spirocyclic tetrahydonaphthyridines (THNs) expanding the chemical space of these important scaffolds for drug discovery.

From Asynt 17 Dec 2024

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.

12 Dec 2024

New tool accelerates drug discovery

The development of molecules to study and treat disease is becoming increasingly burdened by the time and specificity required to analyze the vast amounts of data generated by synthesizing large collections of new molecules.

12 Dec 2024

New technique enables laser light to penetrate deeper into living tissues

Metabolic imaging is a noninvasive method that enables clinicians and scientists to study living cells using laser light, which can help them assess disease progression and treatment responses.

11 Dec 2024

Study pinpoints how a network of different proteins controls rest and activation

Cells in the immune system don't always fight; they often rest and wait for threats, like viruses or bacteria.

11 Dec 2024

New class of antivirals shows promise against multiple viruses

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic - an effective antiviral that has since successfully treated millions.

11 Dec 2024

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).

10 Dec 2024

Scripps Research develops brain-inspired AI for real-time video analysis

Imagine an artificial intelligence (AI) model that can watch and understand moving images with the subtlety of a human brain.

9 Dec 2024

Newcells Biotech raises additional funding from investors

Newcells Biotech (“Newcells”), a leading drug discovery partner specializing in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, today announced it has raised a further £1.2 m from existing investors Mercia Ventures, Northstar Ventures and North East Finance.

From Newcells Biotech 8 Dec 2024